IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v593y2021i7857d10.1038_s41586-021-03412-7.html
   My bibliography  Save this article

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Author

Listed:
  • Dami A. Collier

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge
    University College London)

  • Anna Marco

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Isabella A. T. M. Ferreira

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge)

  • Bo Meng

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge)

  • Rawlings P. Datir

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge
    University College London)

  • Alexandra C. Walls

    (University of Washington)

  • Steven A. Kemp

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge
    University College London)

  • Jessica Bassi

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Dora Pinto

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Chiara Silacci-Fregni

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Siro Bianchi

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • M. Alejandra Tortorici

    (University of Washington)

  • John Bowen

    (University of Washington)

  • Katja Culap

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Stefano Jaconi

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Elisabetta Cameroni

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Gyorgy Snell

    (Vir Biotechnology)

  • Matteo S. Pizzuto

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Alessandra Franzetti Pellanda

    (Clinica Luganese Moncucco)

  • Christian Garzoni

    (Clinica Luganese Moncucco)

  • Agostino Riva

    (University of Milan)

  • Anne Elmer

    (NIHR Cambridge Clinical Research Facility)

  • Nathalie Kingston

    (NIHR Bioresource)

  • Barbara Graves

    (NIHR Bioresource)

  • Laura E. McCoy

    (University College London)

  • Kenneth G. C. Smith

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge)

  • John R. Bradley

    (University of Cambridge
    NIHR Bioresource)

  • Nigel Temperton

    (University of Kent)

  • Lourdes Ceron-Gutierrez

    (Addenbrooke’s Hospital)

  • Gabriela Barcenas-Morales

    (Addenbrooke’s Hospital
    Laboratorio de Inmunologia, UNAM)

  • William Harvey

    (University of Glasgow)

  • Herbert W. Virgin

    (Vir Biotechnology)

  • Antonio Lanzavecchia

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Luca Piccoli

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Rainer Doffinger

    (Addenbrooke’s Hospital
    University of Cambridge)

  • Mark Wills

    (University of Cambridge)

  • David Veesler

    (University of Washington)

  • Davide Corti

    (Humabs Biomed SA, a subsidiary of Vir Biotechnology)

  • Ravindra K. Gupta

    (Cambridge Institute of Therapeutic Immunology & Infectious Disease
    University of Cambridge
    University of Cambridge
    University of KwaZulu Natal)

Abstract

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant1, which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22. We measured neutralizing antibody responses after the first and second immunizations using pseudoviruses that expressed the wild-type spike protein or a mutated spike protein that contained the eight amino acid changes found in the B.1.1.7 variant. The sera from individuals who received the vaccine exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against the B.1.1.7 variant. This reduction was also evident in sera from some patients who had recovered from COVID-19. Decreased neutralization of the B.1.1.7 variant was also observed for monoclonal antibodies that target the N-terminal domain (9 out of 10) and the receptor-binding motif (5 out of 31), but not for monoclonal antibodies that recognize the receptor-binding domain that bind outside the receptor-binding motif. Introduction of the mutation that encodes the E484K substitution in the B.1.1.7 background to reflect a newly emerged variant of concern (VOC 202102/02) led to a more-substantial loss of neutralizing activity by vaccine-elicited antibodies and monoclonal antibodies (19 out of 31) compared with the loss of neutralizing activity conferred by the mutations in B.1.1.7 alone. The emergence of the E484K substitution in a B.1.1.7 background represents a threat to the efficacy of the BNT162b2 vaccine.

Suggested Citation

  • Dami A. Collier & Anna Marco & Isabella A. T. M. Ferreira & Bo Meng & Rawlings P. Datir & Alexandra C. Walls & Steven A. Kemp & Jessica Bassi & Dora Pinto & Chiara Silacci-Fregni & Siro Bianchi & M. A, 2021. "Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies," Nature, Nature, vol. 593(7857), pages 136-141, May.
  • Handle: RePEc:nat:nature:v:593:y:2021:i:7857:d:10.1038_s41586-021-03412-7
    DOI: 10.1038/s41586-021-03412-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-021-03412-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-021-03412-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sue Ann Costa Clemens & Pedro M. Folegatti & Katherine R. W. Emary & Lily Yin Weckx & Jeremy Ratcliff & Sagida Bibi & Ana Verena Almeida Mendes & Eveline Pipolo Milan & Ana Pittella & Alexandre V. Sch, 2021. "Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    2. Sebastian Weigang & Jonas Fuchs & Gert Zimmer & Daniel Schnepf & Lisa Kern & Julius Beer & Hendrik Luxenburger & Jakob Ankerhold & Valeria Falcone & Janine Kemming & Maike Hofmann & Robert Thimme & Ch, 2021. "Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    3. Sissy Therese Sonnleitner & Martina Prelog & Stefanie Sonnleitner & Eva Hinterbichler & Hannah Halbfurter & Dominik B. C. Kopecky & Giovanni Almanzar & Stephan Koblmüller & Christian Sturmbauer & Leon, 2022. "Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Xiaopan Gao & Huabin Tian & Kaixiang Zhu & Qing Li & Wei Hao & Linyue Wang & Bo Qin & Hongyu Deng & Sheng Cui, 2022. "Structural basis for Sarbecovirus ORF6 mediated blockage of nucleocytoplasmic transport," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    5. Wenjuan Dong & Jing Wang & Lei Tian & Jianying Zhang & Erik W. Settles & Chao Qin & Daniel R. Steinken-Kollath & Ashley N. Itogawa & Kimberly R. Celona & Jinhee Yi & Mitchell Bryant & Heather Mead & S, 2023. "Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    6. Meriem Bekliz & Kenneth Adea & Pauline Vetter & Christiane S. Eberhardt & Krisztina Hosszu-Fellous & Diem-Lan Vu & Olha Puhach & Manel Essaidi-Laziosi & Sophie Waldvogel-Abramowski & Caroline Stephan , 2022. "Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    7. Adam Abdullahi & David Oladele & Michael Owusu & Steven A. Kemp & James Ayorinde & Abideen Salako & Douglas Fink & Fehintola Ige & Isabella A. T. M. Ferreira & Bo Meng & Augustina Angelina Sylverken &, 2022. "SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    8. Sapna Sharma & Thomas Vercruysse & Lorena Sanchez-Felipe & Winnie Kerstens & Madina Rasulova & Lindsey Bervoets & Carolien Keyzer & Rana Abdelnabi & Caroline S. Foo & Viktor Lemmens & Dominique Loover, 2022. "Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    9. Leiping Zeng & Yanxia Liu & Xammy Huu Nguyenla & Timothy R. Abbott & Mengting Han & Yanyu Zhu & Augustine Chemparathy & Xueqiu Lin & Xinyi Chen & Haifeng Wang & Draven A. Rane & Jordan M. Spatz & Sake, 2022. "Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    10. Egon A. Ozer & Lacy M. Simons & Olubusuyi M. Adewumi & Adeola A. Fowotade & Ewean C. Omoruyi & Johnson A. Adeniji & Oluseyi A. Olayinka & Taylor J. Dean & Janet Zayas & Pavan P. Bhimalli & Michelle K., 2022. "Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria," Nature Communications, Nature, vol. 13(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:593:y:2021:i:7857:d:10.1038_s41586-021-03412-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.